#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukoencephalopathy Central nervous system neoplasm Dementia Alzheimer's type Cushing's syndrome Dupuytren's contracture Cutaneous lupus erythematosus Idiopathic pulmonary fibrosis Hepato-lenticular degeneration Congenital aplastic anaemia B-cell type acute leukaemia Inborn error of metabolism Antiphospholipid antibodies Progressive multifocal leukoencephalopathy Neoplasm Mantle cell lymphoma stage IV More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy – Trials in Disease Glomerulonephritis membranoproliferative – Basic Information Uterine leiomyosarcoma Leiomyosarcoma metastatic – Treatment Biotinidase deficiency – Trials in Disease Focal segmental glomerulosclerosis Skin angiosarcoma – Treatment Toxic epidermal necrolysis – Diagnostics Myelodysplastic syndrome – Basic Information Progressive multifocal leukoencephalopathy – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Glucose Monohydrate Pyridoxine Pemetrexed Diacid Monohydrate Thiamine Hydrochloride Bp1.7881A 6QC-ICG Ecoo16 Bendamustine Hydrochloride Oxytocin Pristinamycin Dexpanthenol Fludrocortisone INSULIN DEGLUDEC DNL593 Piperacillin Monohydrate Avb-101 Fluvastatin Sodium Cortisone Acetate Ethanol, Anhydrous Narsoplimab More therapies…

    Learn about Your Condition

    Colorectal cancer stage IV Polycystic liver disease Rectal cancer stage III Injection site pain Leiomyosarcoma metastatic Paget's disease of the vulva Metastasis Paedophilia Laryngeal cancer Hypoparathyroidism Intermittent claudication Brain cancer metastatic Hypocalcaemia Chondrosarcoma metastatic Biliary cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Prive Jean Mermoz

Hopital Prive Jean Mermoz

55 Avenue Jean Mermoz, Lyon, 69008, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Capecitabine and Durvalumab for Patients with Removed Biliary Tract Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bile duct cancer
    Investigated Drugs:
    • Capecitabine
    • Durvalumab
    France

  • Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Goserelin
    • Leuprorelin
    • Triptorelin
    France

  • Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colon cancer
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Irinotecan
    France Italy

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Mps-102
    • Mps-103
    Belgium France Germany

  • Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • Olaparib
    • Durvalumab
    • Fulvestrant
    Belgium France Spain
Previous Page
1 … 8 9 10

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!